AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) gapped down prior to trading on Wednesday . The stock had previously closed at $3.67, but opened at $3.90. AcelRx Pharmaceuticals shares last traded at $3.69, with a volume of 3905675 shares.
A number of equities research analysts recently commented on the stock. Zacks Investment Research cut shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 31st. HC Wainwright lifted their price target on shares of AcelRx Pharmaceuticals from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, October 15th. Oppenheimer reaffirmed a “hold” rating on shares of AcelRx Pharmaceuticals in a report on Tuesday, October 9th. Cantor Fitzgerald set a $6.00 price target on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 8th. Finally, B. Riley assumed coverage on shares of AcelRx Pharmaceuticals in a report on Tuesday, October 23rd. They issued a “buy” rating and a $9.00 price target on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. AcelRx Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $7.93.
The company has a market cap of $290.88 million, a price-to-earnings ratio of -3.23 and a beta of 2.03.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its quarterly earnings data on Monday, November 5th. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The company had revenue of $0.38 million for the quarter, compared to analyst estimates of $1.10 million. Equities analysts predict that AcelRx Pharmaceuticals Inc will post -0.82 earnings per share for the current fiscal year.
In related news, insider Lawrence G. Hamel sold 6,953 shares of AcelRx Pharmaceuticals stock in a transaction that occurred on Monday, September 24th. The shares were sold at an average price of $4.50, for a total value of $31,288.50. Following the completion of the transaction, the insider now directly owns 24,371 shares in the company, valued at approximately $109,669.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Badri N. Dasu sold 28,351 shares of AcelRx Pharmaceuticals stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $5.00, for a total transaction of $141,755.00. Following the completion of the transaction, the insider now owns 54,061 shares of the company’s stock, valued at $270,305. The disclosure for this sale can be found here. 25.50% of the stock is currently owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its stake in AcelRx Pharmaceuticals by 2.7% in the 2nd quarter. BlackRock Inc. now owns 673,115 shares of the specialty pharmaceutical company’s stock valued at $2,271,000 after buying an additional 17,737 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of AcelRx Pharmaceuticals during the 2nd quarter valued at $1,676,000. FMR LLC grew its position in shares of AcelRx Pharmaceuticals by 1,094.6% during the 2nd quarter. FMR LLC now owns 298,644 shares of the specialty pharmaceutical company’s stock valued at $1,008,000 after purchasing an additional 273,644 shares in the last quarter. Northern Trust Corp grew its position in shares of AcelRx Pharmaceuticals by 60.8% during the 1st quarter. Northern Trust Corp now owns 91,481 shares of the specialty pharmaceutical company’s stock valued at $192,000 after purchasing an additional 34,584 shares in the last quarter. Finally, Lincoln Capital Corp grew its position in shares of AcelRx Pharmaceuticals by 83.3% during the 3rd quarter. Lincoln Capital Corp now owns 62,775 shares of the specialty pharmaceutical company’s stock valued at $242,000 after purchasing an additional 28,525 shares in the last quarter. Institutional investors and hedge funds own 8.58% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/11/07/acelrx-pharmaceuticals-acrx-shares-gap-down-to-3-90.html.
About AcelRx Pharmaceuticals (NASDAQ:ACRX)
AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.
Featured Article: What is a Stop Order?
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.